Mi Rim Choi

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Owen A. O’Connor, Steven M. Horwitz, Tamás Masszi et al. · Journal of Clinical Oncology · 2015 · 527 citations · Full text

Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated <i>Erwinia</i> asparaginase, pegcrisantaspase: A report from the Children's Oncology Group

Rachel E. Rau, ZoAnn E. Dreyer, Mi Rim Choi et al. · Pediatric Blood & Cancer · 2017 · 63 citations · Full text

Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial

Patrick B. Johnston, Amanda F. Cashen, Petros Nikolinakos et al. · Blood · 2015 · 30 citations

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)

Tamás Pintér, Zandra Klippel, Alvydas Česas et al. · Clinical Colorectal Cancer · 2016 · 28 citations

Gastrointestinal Oncology, Medicine, Phase Iii +10

Recombinant <i>Erwinia</i> asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

Luke Maese, Mignon L. Loh, Mi Rim Choi et al. · Blood · 2022 · 26 citations · Full text

Health Sciences, Antibiotics, Im Jzp458 +15